StockWatch
·

Borosil Ltd Q1 FY27 Results

BOROLTDQ1 FY27 Results
Filing
Result:Weak· Market: Flat#Margin squeeze

Beat/Miss: Miss · Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY26
Revenue253.599.0%
Total Income260.247.3%
Expenditure242.8010.8%
PBT17.4425.7%
Net Profit12.8026.5%
OPM13.59%2.46pp
NPM4.92%2.26pp
EPS1.0726.7%
View full financials

Consumer/manufacturing lens: revenue grew a modest 9% but adjusted PAT fell 26.5% YoY on ~250bps OPM/NPM compression with no offsetting one-offs, missing both street and management's own guidance.

BOROSIL LTD · Q1 FY27 · THE VERDICT

Growth masks profit collapse; margin recovery hinges on pricing power

Borosil posted 9% revenue growth but PAT fell 26.5% YoY. The earnings call reveals why — and exposes the 560-basis-point gap between current margins and FY27 guidance that management must now bridge.

25 Aug 2026 · 6 min read
Reported PAT

₹12.8 Cr

-26.5% YoY

Adjusted PAT

~₹9 Cr

ex ₹4 Cr royalty · ~40% organic decline

EBITDA margin

14.6%

vs 18% FY27 guidance (560bps gap)

On the headline, Borosil delivered 9% revenue growth on volume — solid in a West Asia-disrupted market. But the profit line tells the real story: PAT fell 26.5% despite that revenue tailwind, and once you strip the ₹4 crore royalty income, the organic profit decline hits 40%. This is the quarter's core tension: reported numbers disguise the earnings quality problem.

Where the profit cratered

EBITDA margin compressed 320 basis points to 14.6% from 17.8% year-over-year. Management blames West Asia — fuel and packaging costs cost the company ~₹10 crore in the quarter — and acknowledges pricing power is lagging. The company announced 5–7% price hikes in April, but only ~₹2 crore of the ₹12 crore total cost impact was realized by month-end Q1. That's the crux of the margin story: the cost hit landed immediately; the pricing relief is promised for Q2 onwards.

The question is of getting it realized, there's always a lag.

Revenue composition shows the volume traction: glassware +16.8%, Opalware +9.8%, non-glassware +4.2%. Glassware furnace is running at 90% utilization; Opalware at capacity. The problem is not demand — it is that pricing hasn't caught up to costs, and capacity is tightening.

Management's claims vs. what holds up

9% growth against challenging conditions

Overstated

9% YoY but -11.3% QoQ; PAT fell 26.5% despite revenue growth

West Asia conflict impact ~₹10 Cr

Supported

EBITDA fell ~₹4.3 Cr total YoY; conflict cited as 6 Cr Opal + 2.5 Cr boro

Price hikes 5–7% taken in Q1

Partial

Only ~₹2 Cr realized of ₹12 Cr cost impact; bulk realization Q2 onwards

Hydra plant producing saleable material from 30 June

Supported

2 double-wall lines operational June 30; 3rd line Q2 FY27

Glassware segment 16.8% growth, volume-led

Supported

16.8% confirmed; CFO confirmed volume-led with price lag to Q2

What changed on this call

Capex ratcheted up to ₹125–150 Cr for FY27 (Bharuch glassware ₹42 Cr, borosilicate furnace expansion ₹50 Cr, solar, maintenance). Solar Phase 3 is now live — 20 MW with battery storage commissioned in Q1, raising total solar to 61% of energy needs. Management claims this will deliver ₹27–28 crore of EBITDA savings for FY27.

The Hydra (vacuum-insulated stainless-steel) plant transition to in-house manufacturing via subsidiary Stylenest is no longer aspirational: 2 double-wall lines were operational by quarter-end, with the third coming in Q2. This is material — it hands supply-chain control to Borosil and sidesteps ongoing BIS compliance bottlenecks.

On guidance, the company maintained its long-term 15–20% revenue CAGR target, but the margin outlook tightened slightly. FY27 EBITDA margin guidance sits at ~18% — but now conditional on 'barring West Asia conflict.' This is a meaningful hedge; prior guidance had positioned 18–20% as achievable steady-state. The ROCE target (20–22% medium-term) remains undefined; no quantified bridge or timeframe was offered.

The bull-bear ledger

Why hold
  • Glassware market leadership with 24,000+ retail outlets; +16.8% volume growth proves traction

  • Solar Phase 3 live with ₹27–28 Cr EBITDA tailwind — structural, multi-year margin support

  • Hydra in-house production now underway (Stylenest); supply-chain control unlocked

  • Capex (Bharuch, furnace) is tangible and progressing on schedule (Q3 FY27, Q4 FY28)

  • Anti-dumping investigation ongoing; if tariffs imposed on Chinese imports, margin upside unlocked

Why worry
  • Organic PAT down 40%+ YoY; reported PAT collapse masked by one-time items

  • EBITDA margin 14.6% vs 18% guidance requires 19.8% average Q2–Q4 — 560bps improvement unhistorical

  • Price realization lag (₹2 Cr Q1 of ₹12 Cr impact); bulk 'expected Q2+' but unverified

  • Hydra category only 4.2% growth despite capex; BIS compliance drag persists

  • ROCE stuck at 11% (FY26); ₹150 Cr capex FY27 and ₹92 Cr depreciation will weigh profitability before utilization lifts

  • Chinese borosilicate dumping unresolved; normalized margins remain under pressure despite rupee moves

How the street is positioned

The stock's post-result move is telling. It rose 2.34% on day 1 (Aug 14), then 4.81% by day 3, and 6.15% by day 5. The pop held — the market bought the narrative of volume growth and margin recovery hope. But look beneath: FII ownership is flat at 0.35% quarter-over-quarter. No institutional buyers are stepping in. The stock is still down 28% from its all-time high of ₹363.4, and now sits at ₹261.45, trading above the 200-day simple moving average (₹256.86) by only 2% — a technical warning that the rally is fragile. RSI at 64 signals slight overbought.

This mix — a strong retail pop, flat institutions, still well off the highs, and above the 200-day MA but barely — reads as cautious. The market is willing to give Borosil the benefit of the doubt on margins, but it's not committing capital until Q2 earnings prove the price realization thesis.

Risks ranked by urgency

What could derail the thesis, ordered by severity

Price realization lag extends beyond Q2

High

₹2 Cr realized in Q1 of ₹12 Cr cost impact. If competitor undercutting or demand softness delays realization into Q3, the 18% EBITDA guidance becomes unachievable — forcing a reset and a re-rating lower.

West Asia conflict persists into H2 FY27

High

Fuel costs at 5.8% of sales (vs 2.9% prior year) consume nearly 300 bps of EBITDA margin. Stability in energy costs is embedded in the margin guidance; continuation would add another ₹10 Cr+ of headwinds.

Chinese borosilicate dumping continues unabated

High

Management sees no relief despite rupee depreciation and freight-rate inflation. If anti-dumping investigation is delayed or inconclusive, normalized borosilicate margins (historically 25–30%) will scale down permanently, limiting pricing upside.

Hydra BIS compliance remains a ceiling on category growth

High

Non-glassware (includes Hydra flasks) grew only 4.2% in Q1 despite capex and a new in-house facility. If supply constraints persist or Diwali stocking (Aug–Sep) disappoints, the capex payback model is at risk.

ROCE recovery slower than 20–22% target

Medium

At 11% FY26 with ₹150 Cr capex and ₹92 Cr depreciation incoming, capital productivity will deteriorate before utilization and margins recover. If ROCE stays below 15% through FY27–FY28, investor returns are subordinated.

Inventory overhang from BIS transition takes longer to normalize

Medium

Management acknowledged inventory build for portfolio expansion and BIS compliance. If sell-through remains slow, working-capital drag will pressure cash flow and limit capex optionality.

The debate

The honest read: Borosil is a high-quality brand with real operational tailwinds (solar, volume, capacity expansion) but management credibility has eroded. PAT collapsed despite revenue growth, and management is hedging hard — the 18% EBITDA guidance carries the qualifier 'barring West Asia,' and the ROCE target is a vague 'medium-term aspiration' with no bridge. The market's post-result pop (+6.15% by day 5) suggests retail investors are buying the hope; institutional investors (FII 0.35%) are not. This quarter is Hold on a credibility test: Q2 earnings must validate price realization and Bharuch commissioning must be credible, or the margin guidance reset is overdue. If either disappoints, the stock re-rates lower.

What to watch next

Three concrete tests for Q2–Q3
  • 1 · Q2 FY27 price realization

    Management claims 'bulk' of ₹12 Crore cost realization hits Q2–Q4. The test: does the actual price benefit flow through to Q2 gross margin, or does competitive pressure/demand softness extend the lag further? This single metric determines whether 18% EBITDA is achievable.

  • 2 · Bharuch glassware facility commissioning

    Expected Q3 FY27 (₹42 Cr capex). If commissioning is delayed or ramps at <50% utilization, the capex ROI and medium-term margin bridge are at risk. Watch the commentary for supply-chain readiness and pre-launch customer offtake.

  • 3 · Hydra plant ramp and Diwali stocking

    The third double-wall line goes live Q2 FY27. Diwali stocking (Aug–Sep) is the category's key seasonal test. If non-glassware stays below 5–6% growth in Q2–Q3, the new plant capacity is premature — a red flag on demand fundamentals and capex discipline.

This is not a step-change quarter. Borosil is executing steadily — volume growth is real, capex is progressing, solar is delivering structural EBITDA relief — but the quarter's PAT collapse and margin compression have eroded investor confidence in management's ability to deliver on the 18% guidance without hedges and caveats.

The single number to track from here is FY27 EBITDA margin. It must trend back toward 18% by Q3 FY27 or management's guidance credibility requires reset. Until price realization and Bharuch commissioning are proven, hold at these levels. The opportunity is in Q2 earnings validation, not in chasing today's pop.

Informational and educational content only. Not investment advice.